We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Summit Therapeutics Plc | LSE:SUMM | London | Ordinary Share | GB00BN40HZ01 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 20.50 | 18.00 | 23.00 | - | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
16/8/2018 08:04 | I’m still waiting to average down my holding as I think this could drift lower short term. Would like to get as many as possible to have a better chance of recovering my paper losses over time. I may be wrong as I often am. Great news might come from left field any time. Who knows? | luminoso | |
16/8/2018 07:29 | It's about timing which you probably know. Buy in below 40p and this will shortly have its day again | kirk 6 | |
16/8/2018 07:20 | Don’t be silly hyper ! | the canadian mounted | |
16/8/2018 06:58 | It’s best for some investors to turn the monitor screen off for a while. This is a long term investment and simply requires patience. I’m holding for prepared for 1-2 years for a healthy return on my money.peeps are selling because they can’t wait and haven’t done their research. | the canadian mounted | |
15/8/2018 20:29 | The NASADQ close looks a bit sick & now almost matches the Bid price on AIM today hopefully AIM will hold Thursday clearly we need some positive news from Summit to avoid a further drop in the share price not sure will get it yet.Ever hopeful. | chrisatrdg | |
15/8/2018 09:24 | Actual spread is 32p/35p so 10%. | waterloo01 | |
15/8/2018 09:05 | Pure greed 😡 | the canadian mounted | |
15/8/2018 08:51 | 20% spread? They're not going to attract many punters to clear the overhang with a spread that wide. | phowdo | |
13/8/2018 14:27 | Discuva: Leading The Global Medical Search For New Lifesaving Antibiotics - 6TH July 2015 (NB: The person featured in the film David Williams was the founder of Discuva & following its acquisition by Summit no longer on the payroll but it makes for good background 'reading' & just shows what Summit have acquired - all very good from what I can see) | chrisatrdg | |
12/8/2018 12:29 | I think I might now. You obviously understand these pharma stocks better than I do so if your long here that has given me even more confidence. I'll buy another tranch his week | kirk 6 | |
12/8/2018 12:24 | I would sell all your IMM to buy SUMM, if I was you 🤔 | nobbygnome | |
12/8/2018 12:05 | Wow this company must be good. Will buy another 50k shares this week | kirk 6 | |
12/8/2018 11:51 | I have to admit I joined you all with a small purchase this week. When I saw waterloo was ramping SUMM because of his past failures of scientific analysis 😜, initially I was put off. However, they do seem to be doing the correct things and indeed the antibiotic programs must be worth more than the market cap suggests. Onwards and upwards.....despite waterloo! Nobby | nobbygnome | |
12/8/2018 11:41 | Let the market catch up I don’t give a toss as I’m already in 😁 | the canadian mounted | |
12/8/2018 11:13 | I actually think it should be higher than that after the government grant- what's to say income from government grants combined with a very strong cash balance (currently around 25m taking into consideration cash burn) will see no further need for any dilution certainly not till 2020 anyway. This should be well over £1 and will do a FARN shortly 50p to £1.30 | kirk 6 | |
11/8/2018 22:58 | Got to say this should be around the 75p mark not net cash position. | the canadian mounted | |
11/8/2018 20:12 | Just doing abit of research on the finances . It confirms we are in a really strong finacial position! As at 30 April 2018, total cash and cash equivalents held were GBP27.7 million (31 January 2018: GBP20.1 million). Any thoughts on cash flow positive / negative position ? The last set of quarterly results read well | kirk 6 | |
10/8/2018 12:49 | Detailed below are the slides that went with yesterdays presentation: | chrisatrdg | |
10/8/2018 09:21 | Serepta SEC sch out 6 months 30.06.18 & shows cost on cost share with Summit as being per below of which $2.6 m shown as accrued costs as at 30.06.18: $6.1 million increase in collaboration cost sharing with Summit on its Utrophin platform (of this $2.9m 3 months to 30.06.18). y seeking yy alpha Edit: Extract from call relating to Serepta's results: 'As of January 1, 2018, we started to share 45% of the costs related to Summit’s research and development expenses for the utrophin program. Due to the termination of Summit’s utrophin program during the second quarter of 2018, we expect this expense to significantly decline over the upcoming quarters.' PS I can find no more mention of Summit on reading the script one way of burying bad news. | chrisatrdg | |
10/8/2018 06:47 | BarrieB, that would be an interesting problem IF it came up, but we retain the rights, as far as I'm aware. One reason for killing it so quickly was the likelihood that SRPT said they wouldn't fund their 45% of costs, which would have been a final nail. FDA are currently consulting on antibiotics and how to improve the economics. Could be a boost, depending on what they end up recommending, especially if they match in any way the report from Jom O'Neill a couple of year ago | waterloo01 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions